The clinical trial evaluates a novel combination therapy of Venetoclax, Azacitidine, and Harringtonine for secondary acute myeloid leukemia (sAML), a patient population with limited treatment options. Given the FDA's prior approval of Venetoclax in combination with Azacitidine for elderly patients with newly diagnosed AML, this trial could position the combination as a competitive treatment option for younger patients with sAML. The anticipated enrollment of 30 patients and the focus on efficacy and safety could provide valuable data to support potential market entry. The trial's outcomes may influence treatment guidelines and establish a new standard of care, thereby impacting market dynamics and competitive positioning in the hematologic oncology space.